Showing 1 - 5 results of 5 for search 'Fernando Mandujano', query time: 0.04s Refine Results
  1. 1
    El secreto del hombre invisible. El papel de la invisibilidad conductual en la identidad y el cambio

    El secreto del hombre invisible. El papel de la invisibilidad conductual en la identidad y el cambio by Fernando Mandujano

    Published 2007-05-01
    Get full text
    Article
  2. 2
    El Estado chileno y la Patagonia: una tensa relación en la última frontera interior de América Latina

    El Estado chileno y la Patagonia: una tensa relación en la última frontera interior de América Latina by Fernando Mandujano Bustamante, Juan Carlos Rodriguez Torrent, Sonia Reyes Herrera

    Published 2016-01-01
    Get full text
    Article
  3. 3
    Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

    Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies by Elena E. Perez, Jacques Hébert, Anne K. Ellis, Oral Alpan, William R. Lumry, Ralph Shapiro, Daniel Suez, J. Fernando Mandujano, Richard L. Wasserman

    Published 2021-07-01
    Get full text
    Article
  4. 4
    Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies

    Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficienci... by Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman

    Published 2022-12-01
    Get full text
    Article
  5. 5
    Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

    Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies by Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman

    Published 2019-02-01
    Get full text
    Article

Search Tools: